AssayIndex
Growth-hormone axis peptides

Tesamorelin

TH9507 · Egrifta · trans-3-hexenoyl-GRF (1-44) · C221H366N72O67S · monoisotopic 5131.9276 Da. The index holds 21 assay reports on this compound across 3 batches from 2 suppliers.

21 reports3 batchesmedian 98.43 %index spec 97.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

A 44-residue GHRH analogue with an N-terminal trans-3-hexenoyl group. Long synthesis, moderate achievable purity, and a diagnostic des-acyl impurity 1.4 min early. Coverage is thin (n under 55) and the per-supplier table is not usable; the aggregate median is published with a low-n badge.

Molecular formula
C221H366N72O67S
Monoisotopic mass
5131.9276Da
Average mass
5135.80Da
Residues
44
Nominal retention (RG-2, 30 min)
15.44min
Retention window
0.40min
Counter-ion as usually shipped
acetate
Typical label claims
1 mg · 2 mg · 5 mg
Analytical difficulty (index scale)
1.30 — moderate
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

01722344351656886 Tesamorelin15.44 min · 98.43 % 14.02 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Tesamorelin trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 98.43 % area at the nominal retention time of 15.44 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 21 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 98.43% n=21
Interquartile range 1.75pp n=21
Minimum 95.95% n=21
Maximum 99.72% n=21
Pass rate vs spec 76.2% n=21
Median recovery vs claim 94.1% n=13
Median water 3.95% n=21
Median |mass error| 1.3ppm n=18
012392.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=196.00–96.25 %: n=196.25–96.50 %: n=096.50–96.75 %: n=396.75–97.00 %: n=097.00–97.25 %: n=397.25–97.50 %: n=097.50–97.75 %: n=197.75–98.00 %: n=098.00–98.25 %: n=098.25–98.50 %: n=298.50–98.75 %: n=298.75–99.00 %: n=399.00–99.25 %: n=399.25–99.50 %: n=199.50–99.75 %: n=199.75–100.00 %: n=0median 98.43 Purity (% area) Reports
Figure 2. Purity distribution across all 21 Tesamorelin records. Dashed line is this compound's median (98.43 %); the solid vertical is the index acceptance specification for the growth-hormone axis peptides class (97.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

95.696.497.197.898.699.3100.0ERPERP: Q1 98.53, median 98.80, Q3 99.17, n=12n=12WXTWXT: Q1 96.61, median 96.66, Q3 97.08, n=9n=9 Purity (% area)
Figure 3. Tesamorelin purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-hexenoyl GRF (1-44) (−96 Da)-1.42-96.058100%0.422.36
deamidated (+1 Da)-0.28+0.984100%0.222.88
Met sulfoxide (+16 Da)-0.64+15.995100%0.250.97
truncated (1-40)-1.88-488.259100%0.150.62

Degradation pathways

  • hexenoyl amide hydrolysis
  • Met oxidation
  • Asn deamidation

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Tesamorelin is approved in the United States for HIV-associated lipodystrophy; the pivotal trials were published in 2010.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q30n<3—
2024-Q40n<3—
2025-Q10n<3—
2025-Q20n<3—
2025-Q31n<3—
2025-Q40n<3—
2026-Q1896.6495.95–97.50
2026-Q20n<3—
2026-Q31298.8098.26–99.72

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Tesamorelin records of 21.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042535ERPERP-2604-W7280Janoshik2026-Q399.193.8992.7Supplier-supplied1MARGINAL
AX-2026-042542ERPERP-2604-W7280Janoshik2026-Q398.544.58103.1Supplier-supplied2FAIL
AX-2026-042540ERPERP-2604-W7280Kestrel2026-Q399.723.47103.2Supplier-supplied1MARGINAL
AX-2026-042539ERPERP-2604-W7280Janoshik2026-Q398.774.3089.9Buyer-sourced2MARGINAL
AX-2026-042544ERPERP-2604-W7280VendorInvestigate2026-Q398.803.88—Buyer-sourced2FAIL
AX-2026-042534ERPERP-2604-W7280Janoshik2026-Q399.063.9092.8Supplier-supplied1MARGINAL
AX-2026-042536ERPERP-2604-W7280Janoshik2026-Q398.434.33107.5Supplier-supplied2FAIL
AX-2026-042543ERPERP-2604-W7280PeptideMeter2026-Q399.164.03—Supplier-supplied0PASS
AX-2026-042537ERPERP-2604-W7280PeptideMeter2026-Q398.523.9594.1Supplier-supplied1MARGINAL
AX-2026-042538ERPERP-2604-W7280Kestrel2026-Q398.264.37—Supplier-supplied1MARGINAL
AX-2026-042545ERPERP-2604-W7280Janoshik2026-Q399.323.85101.4Supplier-supplied2FAIL
AX-2026-042541ERPERP-2604-W7280PeptideMeter2026-Q398.793.70—Supplier-supplied1MARGINAL
AX-2026-043409WXTWXT-2601-A4454Janoshik2026-Q196.143.32—Buyer-sourced1FAIL
AX-2026-043412WXTWXT-2601-A4454VendorInvestigate2026-Q196.663.8189.3Buyer-sourced1FAIL
AX-2026-043411WXTWXT-2601-A4454Janoshik2026-Q197.053.56—Supplier-supplied1MARGINAL
AX-2026-043414WXTWXT-2601-A4454PeptideMeter2026-Q197.084.8489.6Buyer-sourced2MARGINAL
AX-2026-043413WXTWXT-2601-A4454Janoshik2026-Q196.614.25—Supplier-supplied1FAIL
AX-2026-043415WXTWXT-2601-A4454VendorInvestigate2026-Q195.953.8999.1Buyer-sourced1FAIL
AX-2026-043410WXTWXT-2601-A4454Medutest2026-Q197.504.23—Supplier-supplied1MARGINAL
AX-2026-043408WXTWXT-2601-A4454Janoshik2026-Q196.634.0597.5Buyer-sourced1FAIL
AX-2025-021136WXTWXT-2505-B5419Janoshik2025-Q397.094.9091.6Supplier-supplied1MARGINAL